PERSON DIRECTORY
Martin Shkreli
Martin Shkreli appears in 1 indexed conversation across Gradient Dissent. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
From pharma to AGI hype, and developing AI in finance: Martin Shkreli’s journey
AI’s largest biopharma opportunity may be target selection rather than molecule generation, with an LLM reading roughly 36-38 million PubMed papers to identify overlooked clinical opportunities.BTK illustrates the mechanism: valuable research sat published for 15-20 years, while clinical trials still consume 50-70% of total cost and development cycles approach ten years.Shkreli’s finance suite found millions of dollars in revenue after abandoning forced AI positioning, but breaking-news advantages may diffuse across Wall Street within six months to a year.